Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734620 | 0.90 | RARA (0.32) | PSMB5MAPTPDE3BPDE3A | |
| SCHEMBL17734517 | 0.89 | ESR1 (0.39) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734832 | 0.89 | ESR1 (0.39) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734494 | 0.89 | ESR1 (0.39) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734823 | 0.89 | ESR1 (0.39) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734492 | 0.87 | ESR1 (0.40) | ESR1ENPP3ENPP1PSMB5CRHR1 | |
| SCHEMBL17734533 | 0.86 | ESR1 (0.38) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734498 | 0.86 | ESR1 (0.38) | ESR1CRHR1MAPTNPC1ALDH1A1 | |
| SCHEMBL17734829 | 0.86 | ESR1 (0.38) | ESR1PSMB5CRHR1MAPTTACR1 | |
| SCHEMBL17734822 | 0.86 | ESR1 (0.39) | ESR1CRHR1MAPTTACR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | ARL1, CCNL2, APOL1 | ESR1 15/4885PTAFR 4800/4885ENPP3 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.